List of Excipients in Branded Drug RADIOGENIX SYSTEM

RADIOGENIX SYSTEM Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 30, 2026

The RADIOGENIX SYSTEM is a radiopharmaceutical production platform, not a conventional finished-dose drug. Its commercial value comes from producing technetium Tc 99m through proton irradiation of enriched molybdenum-100, then supplying sodium pertechnetate Tc 99m injection for preparation of diagnostic radiopharmaceuticals. Excipient strategy is therefore limited to the final injectable formulation, generator processing fluids, radiochemical purity, and compatibility with downstream labeling kits. The largest commercial opportunities are decentralized isotope production, reduced reliance on reactor-based molybdenum-99, and integration with hospital radiopharmacies.

What is the RADIOGENIX SYSTEM and what drug product does it produce?

The RADIOGENIX SYSTEM is an FDA-approved system for producing technetium Tc 99m. NorthStar Medical Radioisotopes developed the system as an alternative to conventional uranium-fission or reactor-based molybdenum-99/technetium-99m generators.

Attribute	RADIOGENIX SYSTEM
Sponsor	NorthStar Medical Radioisotopes LLC
FDA product	RADIOGENIX SYSTEM
Active radionuclide	Technetium Tc 99m
Precursor	Enriched molybdenum-100
Production route	Proton irradiation using the Mo-100(p,2n)Tc-99m reaction
Finished radiopharmaceutical	Sodium pertechnetate Tc 99m injection
FDA approval	December 2018
Regulatory pathway	NDA 212155
Primary use	Preparation of Tc-99m diagnostic radiopharmaceuticals
Therapeutic category	Diagnostic radiopharmaceutical production system

Technetium Tc 99m is used in a broad range of nuclear medicine procedures, including bone, cardiac, renal, hepatobiliary and pulmonary imaging. It is also used to reconstitute commercial kits such as technetium Tc 99m sestamibi, pentetate, medronate and sulfur colloid.

The system’s commercial product is not equivalent to a standard injectable drug manufactured in a centralized plant. It combines equipment, radionuclide production, radioactive-material handling, quality control and final-dose preparation.

What excipients are used with the RADIOGENIX SYSTEM?

The most relevant final-product formulation is sodium pertechnetate Tc 99m injection in a sterile isotonic aqueous vehicle. Sodium chloride is the principal formulation excipient or tonicity agent identified in standard sodium pertechnetate injectable presentations. The formulation is generally designed to minimize chemical impurities, radiolysis, metal contamination and interference with downstream kit labeling.

Formulation element	Function	Strategic relevance
Sodium pertechnetate Tc 99m	Active radioactive ingredient	Must meet radionuclidic, radiochemical and chemical purity requirements
Sodium chloride solution	Isotonic vehicle	Supports intravenous administration and kit reconstitution
Water for injection	Solvent	Must meet sterile injectable quality standards
pH control, where applicable	Maintains formulation stability	Must not impair Tc-99m chemistry or kit performance
Preservatives	Generally avoided in single-use radiopharmaceutical presentations	Reduce compatibility and regulatory risk
Chelators or stabilizers	Not ordinarily part of the basic pertechnetate injection	May alter biodistribution or interfere with labeling

The excipient strategy should prioritize chemical neutrality rather than formulation complexity. Every added component creates potential risks involving radiochemical purity, labeling efficiency, biodistribution, sterility, extractables, adsorption to tubing and compatibility with automated dispensing systems.

What formulation properties matter most?

The critical quality attributes are:

1. Sterility and bacterial endotoxin control.
2. Radionuclidic purity.
3. Radiochemical purity.
4. Chemical purity, including residual molybdenum and metallic contaminants.
5. pH and isotonicity.
6. Absence of particulate matter.
7. Compatibility with approved Tc-99m kits.
8. Stability over the usable activity window.
9. Dose-calibration accuracy.
10. Low adsorption to containers, syringes and transfer lines.

For a generator-derived or accelerator-produced isotope, the formulation cannot be evaluated separately from the production process. Target materials, accelerator components, separation chemistry, tubing, collection vessels and elution conditions can all influence the final injectable product.

How should an excipient strategy be designed for commercial scale?

A commercially robust strategy should use the smallest viable excipient set and lock the formulation to a validated container-closure and dispensing system.

1. Use a low-complexity aqueous formulation

A sodium chloride-based isotonic vehicle is commercially attractive because it is familiar to regulators, hospitals and radiopharmacy operators. It also minimizes the number of new toxicology, compatibility and stability studies.

2. Avoid unnecessary preservatives

Preservatives can create problems in injectable radiopharmaceuticals, especially when the product is used to reconstitute multiple kits. They can alter labeling chemistry, introduce patient-safety concerns and complicate compatibility claims.

3. Validate kit compatibility

The formulation must support consistent reconstitution of third-party Tc-99m kits. NorthStar’s commercial opportunity is stronger if its pertechnetate can be used across the same kit portfolio served by conventional Tc-99m generators.

4. Control radiolysis

Tc-99m products are exposed to ionizing radiation during storage. Radiolysis can produce reactive oxygen species and degrade container materials or formulation components. A simple formulation reduces this risk. Where stabilizers are considered, they must be evaluated for effects on radiochemical purity, biodistribution and kit labeling.

5. Develop container and delivery-system IP

The strongest formulation-adjacent opportunities may not involve a new excipient. They may involve:

• Low-adsorption vials and syringes.
• Shielded multi-dose containers.
• Automated elution and dispensing cartridges.
• Closed-system transfer devices.
• Tubing materials that reduce radionuclide retention.
• Single-use sterile collection assemblies.
• Long-life sterile fluid paths.
• Integrated dose calibration and quality-control modules.

These technologies can create recurring consumables revenue while supporting system switching costs.

What patents protect the RADIOGENIX SYSTEM?

The relevant intellectual-property estate is likely to span the production system rather than a conventional composition-of-matter patent.

Potential claim categories include:

IP category	Commercial subject matter
Isotope production	Mo-100 target irradiation and Tc-99m generation
Target engineering	Enriched molybdenum target form, geometry and thermal management
Chemical separation	Recovery of Tc-99m from irradiated molybdenum
Generator architecture	Integrated accelerator, target, separation and dispensing equipment
Automation	Remote operation, shielding, dose measurement and process control
Consumables	Cartridges, tubing, target assemblies and collection vessels
Quality control	Assays for radionuclidic and radiochemical purity
Formulation	Sodium pertechnetate composition, container and stability features
Use patents	Use of accelerator-produced Tc-99m in diagnostic imaging or kit preparation

The public FDA approval establishes regulatory authorization but does not itself identify a complete enforceable patent estate. The Orange Book should be reviewed for any listed patents associated with NDA 212155. A system-based product may also rely on patents outside the Orange Book, including equipment, process, manufacturing and licensing rights.

How strong is the patent estate for the RADIOGENIX SYSTEM?

Patent strength is likely strongest in the integrated production architecture and weakest in the basic sodium pertechnetate formulation. Sodium chloride, water for injection and pertechnetate itself are unlikely to provide durable composition-of-matter exclusivity.

The principal barriers to competition are more likely to be:

• Access to enriched Mo-100.
• Accelerator and target-engineering know-how.
• Radioactive-material licenses.
• Sterile manufacturing capability.
• Validated separation chemistry.
• Hospital installation requirements.
• Quality systems and regulatory history.
• Service infrastructure.
• Supply contracts and customer qualification.

This creates a hybrid moat. Patents matter, but operational execution and regulatory compliance may be more difficult to replicate than the basic formulation.

When does RADIOGENIX lose exclusivity?

The product received FDA approval in December 2018. FDA approval alone does not establish a fixed market-exclusivity date for the system. Exclusivity depends on the specific statutory designation recorded for the NDA, any listed patents, pediatric extensions and patent-term adjustments.

Exclusivity element	Relevance to RADIOGENIX
New chemical entity exclusivity	Unlikely to be the primary protection because Tc-99m and sodium pertechnetate are established substances
New drug exclusivity	May be relevant depending on FDA’s approval classification
Orphan exclusivity	Not expected for a broad diagnostic isotope-production system
Pediatric exclusivity	Applies only if separately granted
Patent term	Depends on individual U.S. patent grant and adjustment dates
Device protection	May exist outside the Orange Book through equipment and process patents
Regulatory know-how	Strong practical value but not statutory exclusivity

A competitor could enter without reproducing the exact system by supplying reactor-produced Tc-99m, operating a competing accelerator platform or using another production and separation process. The relevant market therefore has multiple entry routes.

What is the Orange Book status of the RADIOGENIX SYSTEM?

The RADIOGENIX SYSTEM is associated with FDA NDA 212155. Orange Book analysis should distinguish between:

1. The listed drug product, sodium pertechnetate Tc 99m injection or related system designation.
2. Patents listed by the NDA holder.
3. Method-of-use patents.
4. Patents covering equipment or manufacturing processes that may not be listed.
5. Exclusivity codes and expiration dates recorded by FDA.

An Orange Book listing does not capture every patent that could affect market entry. Accelerator equipment, target fabrication, isotope separation and automated dispensing patents may be enforceable without being listed against the approved product.

Are Paragraph IV challenges likely for RADIOGENIX?

A conventional Paragraph IV challenge is less straightforward than with an oral small-molecule medicine. The likely competitors are not simply generic-drug manufacturers filing ANDAs. They may be:

• Other accelerator-based Tc-99m producers.
• Reactor and generator suppliers.
• Radiopharmacy networks.
• Equipment manufacturers.
• Hospitals developing in-house production.
• Companies commercializing alternative isotope platforms.

If an ANDA pathway is unavailable or commercially unattractive, competitors may pursue 505(b)(2), NDA, device-plus-drug strategies or independent licensing and manufacturing routes. The practical litigation risk is therefore more likely to concern patent infringement, regulatory approval and supply contracts than a standard Abbreviated New Drug Application dispute.

What formulation patents could protect future RADIOGENIX products?

The strongest formulation claims would likely require a measurable technical distinction, such as:

• Improved stability during the activity window.
• Reduced radiolysis.
• Higher recovery from the collection vessel.
• Better compatibility with specific labeling kits.
• Reduced molybdenum breakthrough.
• Lower metal contamination.
• Improved container-closure performance.
• Extended usability after collection.
• Automated sterile dispensing with reduced operator exposure.

A claim covering only sodium pertechnetate in normal saline would face substantial validity and freedom-to-operate pressure because the components and use environment are established. Commercially meaningful claims should connect composition with a demonstrated performance benefit.

What commercial opportunities exist for excipients and consumables?

The largest excipient opportunity is not a premium novel excipient. It is a qualified supply platform built around sterile fluids, containers and consumables.

Hospital radiopharmacy supply

Hospitals can use locally produced Tc-99m to reduce dependence on centralized generator deliveries. A validated sterile saline and collection-cartridge supply chain could produce recurring revenue.

Kit compatibility services

A supplier could offer compatibility packages covering major Tc-99m labeling kits. This would reduce adoption barriers for hospitals and radiopharmacies.

Closed-system consumables

Disposable sterile cartridges, shielded vials and low-retention tubing can create recurring revenue after the capital equipment is installed.

Contract manufacturing

NorthStar or partners could manufacture sterile formulation components, target assemblies and collection systems for regional radiopharmacy networks.

International deployment

Geographic opportunity is strongest in markets with:

• Limited access to reactor-produced Mo-99.
• High nuclear-medicine procedure volume.
• Existing cyclotron infrastructure.
• Regulatory acceptance of accelerator-produced Tc-99m.
• Hospital capacity for radioactive-material handling.

The United States remains the primary reference market because FDA approval reduces regulatory uncertainty. Expansion into Europe, Canada, Asia-Pacific and the Middle East would require country-specific radiopharmaceutical, radioactive-material and medical-device approvals.

How does RADIOGENIX compare with conventional Tc-99m generators?

Factor	RADIOGENIX SYSTEM	Conventional Mo-99/Tc-99m generator
Production source	Accelerator-produced Tc-99m	Generator elution from Mo-99
Key precursor	Mo-100	Mo-99
Infrastructure	Accelerator and target system	Generator logistics and elution station
Supply model	Local or regional production	Centralized generator distribution
Main risk	Capital, licensing and operational complexity	Reactor supply, transport and Mo-99 availability
Formulation	Sodium pertechnetate injection	Sodium pertechnetate injection
Excipient differentiation	Limited	Limited
Recurring revenue	Consumables, service and sterile assemblies	Generator replacement and service
Competitive moat	Production process and installed system	Reactor access, logistics and contracts

The final Tc-99m formulation is similar in commercial function, but the supply-chain economics differ. RADIOGENIX may be more attractive where local isotope production offsets transport delays, generator costs or supply interruptions.

What generic launch risks exist for RADIOGENIX?

The principal launch risks are not equivalent to generic substitution of a tablet. They include:

• A competing Tc-99m production platform.
• Conventional generator price reductions.
• Hospital reluctance to purchase accelerator infrastructure.
• Inadequate daily procedure volume.
• Short product shelf life.
• Radioactive-material licensing delays.
• Sterility failures or radiochemical impurity excursions.
• Incompatibility with high-volume labeling kits.
• Limited availability of enriched Mo-100.
• Service interruptions affecting installed equipment.

The most credible competitive entry scenario is a regional provider that combines accelerator production, radiopharmacy operations and hospital contracts. Such a provider could compete on guaranteed dose availability rather than on excipient formulation.

What patent litigation and settlement issues matter?

Litigation exposure should be assessed across four layers:

1. Patent infringement involving isotope-production methods.
2. Trade-secret disputes involving target processing or separation chemistry.
3. Equipment and cartridge patent disputes.
4. Contract litigation involving supply, service and exclusivity arrangements.

Settlement agreements could include field-of-use licenses, geographic restrictions, cross-licenses, supply commitments and royalty-bearing equipment sales. These terms may materially affect commercial entry even when the basic drug formulation is not patent-protected.

Key Takeaways

• RADIOGENIX SYSTEM is an accelerator-based Tc-99m production platform, not a conventional finished-dose pharmaceutical.
• Its final drug product is sodium pertechnetate Tc 99m injection, generally supplied in a sterile isotonic aqueous formulation.
• Excipient differentiation is limited; the strongest opportunities are in sterile consumables, containers, tubing, cartridges and automated dispensing.
• The patent estate is likely more important for isotope production, target engineering, separation chemistry and system architecture than for sodium chloride-based formulation.
• Orange Book analysis should be supplemented with equipment, process, manufacturing and licensing review.
• Paragraph IV risk is less central than competition from alternative Tc-99m production systems and conventional generator suppliers.
• Commercial value depends on installed infrastructure, regulatory approvals, service capability, enriched Mo-100 access and hospital utilization.
• Biosimilar risk is not applicable. The relevant competitors are alternative isotope suppliers, radiopharmacy operators and generator manufacturers.

FAQs

Is the RADIOGENIX SYSTEM a drug or a medical device?

It is a drug-production system approved for generating technetium Tc 99m used in diagnostic radiopharmaceutical preparation. Its regulatory profile combines drug, radioactive-material and equipment considerations.

Does RADIOGENIX use a novel excipient?

The commercial formulation does not depend on a novel excipient. The formulation strategy centers on sterile isotonic aqueous media, compatibility and radiochemical purity.

Can generic manufacturers copy RADIOGENIX?

A competitor would need to reproduce or design around the production process, equipment architecture, separation chemistry and regulatory requirements. A simple generic formulation filing would not replicate the full system.

Is technetium Tc 99m protected by a composition-of-matter patent?

Technetium Tc 99m and sodium pertechnetate are established radiopharmaceutical substances. Any durable protection is more likely to arise from production methods, system integration, consumables or specialized formulations.

What is the best commercial opportunity around RADIOGENIX?

The strongest opportunity is a recurring-revenue platform combining accelerator installation, sterile single-use consumables, service contracts, quality-control software and validated compatibility with high-volume Tc-99m labeling kits.

References

1. U.S. Food and Drug Administration. (2018). RADIOGENIX SYSTEM: Prescribing information and approval materials, NDA 212155. https://www.accessdata.fda.gov/scripts/cder/daf/

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

3. NorthStar Medical Radioisotopes, LLC. (n.d.). RADIOGENIX SYSTEM. https://www.northstarnm.com/

4. U.S. Pharmacopeia. (2024). General chapter <823>: Positron emission tomography drugs for compounding, dispensing, and repackaging. United States Pharmacopeial Convention.

5. U.S. Nuclear Regulatory Commission. (n.d.). Medical use of radioactive material and radiopharmaceutical regulation. https://www.nrc.gov/materials/miau/med-use.html